RxDoctor Payments Data

Cesar Vazquez Muniz, MD

Cardiovascular Disease · Humacao, PRNPI 1295734390

Payments from drug & device makers

$1,333in general payments, 2019–2025

Across 68 payments — averaging $19.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$532
  • E.r. Squibb & Sons, L.L.C.$254
  • Boehringer Ingelheim$205
  • AstraZeneca$159
  • PBG Puerto Rico LLC$153
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$31

What the payments were for

  • Food & beverage$1,328100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,333 in reported general payments places this provider in the 35th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$10,525
Medicare patients
36
Services billed
233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban189$123,925
XareltoRivaroxaban153$100,967
EntrestoSacubitril/Valsartan45$34,016
JardianceEmpagliflozin48$32,467
BrilintaTicagrelor39$20,570
FarxigaDapagliflozin Propanediol22$16,026
Candesartan Cilexetil200$15,487
SynthroidLevothyroxine Sodium129$8,338
Rosuvastatin Calcium950$7,958
Janumet XrSitagliptin Phos/Metformin Hcl16$7,893
Metoprolol Succinate564$6,480
Irbesartan311$6,241
Amlodipine Besylate983$5,219
Ezetimibe344$4,586
Omega-3 Acid Ethyl Esters111$4,451

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$532$100,967153 claims
AstraZenecaBrilinta, Farxiga, Atacand, Crestor$159$43,66785 claims
Boehringer IngelheimJardiance, Jentadueto$205$35,65260 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in Humacao

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →